Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

By F. Edelmann, R. Wachter, A. Schmidt, E. Kraigher‐Krainer, C. Colantonio, W. Kamke, A. Duvinage, R. Stahrenberg, Kathleen Durstewitz, M. Löffler and 7 more. Journal of the American Medical Association (JAMA), 2013

743 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/f7f6480f009d5ceabcc05d032d952f33a77995d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Endocrinology, Diabetes and Metabolism

Véronique L. Roger

Citations in the corpus

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, methodology): “Trials using comparable and efficacious agents for HFrEF have generally been disappointing when used in patients with HFpEF (590).”
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “Mechanistic studies have suggested that mineralocorticoid receptor antagonists can improve measures of diastolic function in patients with HFpEF, possibly by a similar effect on remodeling (83,168).”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, methodology): “Several criteria have been proposed to define the syndrome of HFpEF.”